Table 3.
rhC1-INH dosing.
| All patients (N = 71) | All attacks (N = 2356) | First attack (n = 71) | Single location (n = 2242) | Two locations (n = 109) | Three locations (n = 5) |
|---|---|---|---|---|---|
| Dose, mean | |||||
| Number of units (U) | 3307 | 3107 | 3336 | 2749 | 2520 |
| U/kg | 43.3 | 40.7 | 43.6 | 38.0 | 35.1 |
| Number of doses, n (%) | |||||
| One | 2351 (99.7) | 70 (98.6) | 2239 (99.9) | 107 (98.2) | 5 (100) |
| Two |
5 (0.2) |
1 (1.4) |
3 (0.1) |
2 (1.8) |
0 (0) |
|
Patients <84 kg (n = 49) |
All attacks (n = 1842) |
First attack (n = 49) |
Single location (n = 1741) |
Two locations (n = 96) |
Three locations (n = 5) |
| Dose, mean | |||||
| Number of units (U) | 3083 | 2873 | 3113 | 2575 | 2520 |
| U/kg | 43.5 | 42.0 | 43.9 | 37.3 | 35.1 |
| Number of doses, n (%) | |||||
| One | 1838 (99.8) | 48 (98.0) | 1738 (99.8) | 95 (99.0) | 5 (100) |
| Two |
4 (0.2) |
1 (2.0) |
3 (0.2) |
1 (1.0) |
0 (0) |
|
Patients ≥84 kg (n = 22) |
All attacks (n = 514) |
First attack (n = 22) |
Single location (n = 501) |
Two locations (n = 13) |
Three locations (n = 0) |
| Dose, mean | |||||
| Number of units (U) | 4110 | 3627 | 4112 | 4038 | – |
| U/kg | 42.7 | 38.6 | 43.0 | 42.5 | |
| Number of doses, n (%) | |||||
| One | 513 (99.8) | 22 (100) | 501 (100) | 12 (92.3) | – |
| Two | 1 (0.2) | 0 (0) | 0 (0) | 1 (7.7) |
During 1 HAE attack, rhC1-INH dosing was limited to 14 U/kg (total dose, 1050 U) because the patient presented with poor venous access; this oro-facial-pharyngeal attack showed improvement within 4 h. Also, during 1 HAE attack, a patient received 3 consecutive vials, recorded as a single treatment, for a total rhC1-INH dose of 117 U/kg. HAE: hereditary angioedema, rhC1-INH: recombinant human C1-esterase inhibitor